Enlivex Ltd.
ENLVHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeEnlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. With a market capitalization of $3.5M, it sits in micro-cap territory. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Market Cap
$3.5M
Beta
1.41
P/E (TTM)
0.00
P/E (Fwd)
-0.22
EPS (TTM)
$428.97
EPS (Fwd)
$-0.78
ROE
162.9%
ROA
-0.6%
Cash
$5.5M
Total Debt
$17.5M
Free CF
-$3.74B
52W Change
-98.9%
Annual Financials
Cash vs Debt
Where ENLV stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ENLV finished 97.04% below its 150-day moving average ($7.10) and 97.74% below its 200-day moving average ($9.28). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ENLV overbought or oversold?
At the October 20, 2026 close, ENLV's RSI(14) was 9.7, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Enlivex Ltd. carries $17.5M in total debt against $5.5M in cash reserves — debt is roughly 3.2x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$3.74B. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 162.9%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Enlivex Ltd. and its sector.